← Back to list
MA05.006l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Effective date
Dec 29, 2025
Identified
Oct 29, 2026
Summary
Independence Blue Cross reissued MA05.006l on 10/28/2026 to communicate its continuing position on TENS coverage; the policy itself became effective 12/29/2025 with clarified medically necessary criteria for chronic pain (other than low back pain) and revised experimental/investigational criteria. A specific criterion requiring ≥50% pain reduction has been deleted from the medically necessary section, streamlining approval requirements for TENS trial periods.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 3 steps
01Already effective 2025-12-29: Verify that billing staff have implemented the revised TENS coverage criteria for Independence Blue Cross Medicare Advantage plans, specifically: (1) confirm that the 30–60-day TENS trial for chronic pain (other than low back pain) no longer requires documentation of ≥50% pain reduction before approval, and (2) update internal approval workflows to reflect that trial success is now monitored by professional provider documentation of likelihood of significant therapeutic benefit, not retroactive pain-reduction metrics.
02Billing team should validate that claims for E0720 and E0730 during trial periods are submitted as rentals only, and that post-trial coverage is processed as purchase once monitoring criteria are met.
03Since this is a reissue with no substantive changes (reissued 10/28/2026 to communicate continuing position), confirm current applicability of the 12/29/2025 effective criteria with Independence Blue Cross and review Attachment A (referenced but not provided) for experimental/investigational diagnosis codes to ensure claims are not submitted for excluded conditions.
Codes mentioned
E0720E0730A4556A4557A4558A4595A4630G89.12G89.18G89.21G89.29G89.3G89.4
Original notice
MA05.006l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesLowEffective Dec 29, 2025 · Medical PolicyMA05.006k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesMediumEffective Oct 1, 2025 · Medical Policy05.00.74k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesLowEffective Oct 1, 2025 · Medical Policy05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesMediumEffective Dec 29, 2025 · Medical PolicyBrowse every Independence Blue Cross change in the policy list